This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (9)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • Oncology  • Head & Neck Cancer  • Neoplasms of Head & Neck  • Radiation Therapy  • Alert me on articles by topic  Social Bookmarking   What's this?

Jean-Michel Prades, MD, PhD; Thierry M. Schmitt, MD; Andrei P. Timoshenko, MD; Pierre-Gilles Simon, MD; Joanne de Cornulier, MD; Marc Durand, MD; Aline Guillot, MD; Christian Martin, MD

Arch Otolaryngol Head Neck Surg. 2002;128:384-388.

Objectives  To test the effectiveness of concurrent chemoradiotherapy in patients with pyriform sinus carcinoma and to demonstrate the feasibility of an organ preservation approach.

Design  Clinical trial phase 2.

Setting  University Hospital Center, St-Etienne, France.

Patients  The study population comprised 46 male patients with resectable stage III and IV pyriform sinus carcinoma.

Methods  Two successive chemoradiation regimens were investigated. In protocol 1 (24 patients), carboplatin was given on days 1 through 5 and 28 through 33, with an area under the curve dose of 5 mg/mL for 1 minute per day and bifractionated radiotherapy (160 rad [1.6 Gy]/fraction) delivered on days 1 through 16 and 28 through 38. A treatment break was planned on days 16 through 27. In protocol 2 (22 patients), chemotherapy was given with the same dose of carboplatin on days 1 and 21, and fluorouracil (750 mg/m² per day) on days 1 through 7 and 21 through 28. Radiotherapy with a single fraction of 180 rad (1.8 Gy)/d was delivered during the first 2 weeks and then 150 rad (1.5 Gy) twice a day during the next 3 weeks.

Main Outcome Measures  Patients were evaluated for tumor response, toxic reactions, and organ preservation and survival rates. Statistical analysis of disease-free survival and overall survival was performed using the Kaplan-Meier method.

Results  A complete response was noted in 21 (88%) of the 24 patients following protocol 1 and 16 (73%) of the 22 patients following protocol 2. After 2 years of follow up, 16 patients (67%) (protocol 1) and 12 patients (55%) (protocol 2) retained their larynx without evidence of disease. During therapy, 15 patients (63%) (protocol 1) and 19 patients (86%) (protocol 2) required unplanned hospitalization for toxic effects. The overall survival and disease-free survival rates at 2 years were 58% (protocol 1) vs 53% (protocol 2) and 39% (protocol 1) vs 41% (protocol 2) (P = .80), respectively.

Conclusion  Concomitant chemotherapy and bifractionated radiotherapy, although toxic, leads to good locoregional control and therefore to a significant level of laryngeal preservation.

From the Departments of Otolaryngology–Head and Neck Surgery (Drs Prades, Timoshenko, Simon, Durand, and Martin), Radiation Oncology (Drs Schmitt and de Cornulier), and Medical Oncology (Dr Guillot), Saint-Etienne University Hospital Center, Bellevue Hospital, St-Etienne, France.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLE

Archives of Otolaryngology–Head & Neck Surgery Reader's Choice: Continuing Medical Education
Arch Otolaryngol Head Neck Surg. 2002;128(4):465-466.
FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Surgical Wound Complications After Intensive Chemoradiotherapy for Advanced Squamous Cell Carcinoma of the Head and Neck
Morgan et al.
Arch Otolaryngol Head Neck Surg 2007;133:10-14.
ABSTRACT | FULL TEXT  

Correct Carboplatin Dose?
Loughner
Arch Otolaryngol Head Neck Surg 2003;129:1351-1351.
FULL TEXT